Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800118 | 0.87 | CA2 (0.52) | CYP3A4CYP2C9GRIK1GRIA2GRIA4 | |
| SCHEMBL800588 | 0.84 | ALDH1A1 (0.47) | CYP3A4CYP2C9TSHRGRIK1GRIA2 | |
| SCHEMBL800491 | 0.82 | NAPRT (0.57) | CYP3A4CYP2C9L3MBTL1CYP1A2 | |
| SCHEMBL9619650 | 0.82 | ALDH1A1 (0.52) | GRIK1ALDH1A1MAPK1L3MBTL1MEN1 | |
| SCHEMBL800077 | 0.82 | HTT (0.54) | CYP3A4ALDH1A1L3MBTL1CTBP2POLB | |
| SCHEMBL800076 | 0.82 | PLA2G10 (0.45) | CYP3A4CYP2C9TSHRGRIK1GRIA2 | |
| SCHEMBL7923429 | 0.80 | CYP3A4 (0.66) | CYP3A4CYP2C9TSHRCES2CES1 | |
| SCHEMBL367454 | 0.80 | CYP3A4 (0.66) | CYP3A4CYP2C9TSHRCES2CES1 | |
| SCHEMBL265774 | 0.80 | CYP3A4 (0.66) | CYP3A4CYP2C9TSHRCES2CES1 | |
| SCHEMBL800058 | 0.80 | CTBP2 (0.51) | GRIK1GRIA2GRIA4GRIK3GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069720-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | CYP3A4 1281/4885CYP2C9 864/4885TSHR 4198/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | CYP3A4 1708/4885CYP2C9 1554/4885TSHR 4034/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | CYP3A4 1259/4885CYP2C9 847/4885TSHR 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.